Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
XOMA Royalty Corporation (Nasdaq: XOMA) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its royalty aggregation business, capital structure, and transaction activity. On this page, you can review XOMA Royalty’s SEC filings alongside AI-powered summaries that help explain the key points in accessible language.
For investors analyzing XOMA Royalty, Form 10-K annual reports and Form 10-Q quarterly reports provide detail on royalty and milestone receipts, portfolio composition, risk factors, and accounting for acquired economic interests. Form 8-K current reports document material events such as the completion of acquisitions of HilleVax, LAVA Therapeutics, and Mural Oncology, entry into at-the-market sales agreements for common and preferred stock, and announcements of financial results.
XOMA Royalty’s filings also describe its listed securities, including common stock (XOMA) and preferred instruments such as 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) and depositary shares representing 8.375% Series B Cumulative Perpetual Preferred Stock (XOMAO). Related registration statements and prospectus supplements outline how proceeds from these offerings may be used to acquire additional potential royalty and milestone revenue streams, fund preferred dividends, and support general corporate purposes.
In addition, Form 4 insider transaction reports and proxy materials can provide insight into equity ownership and governance, while exhibits to 8-K filings include key agreements such as merger agreements, share purchase agreements, contingent value rights agreements, and sales agreements. Stock Titan’s interface enhances these filings with AI-generated highlights that point out important terms, transaction structures, and potential implications for XOMA Royalty’s royalty and milestone portfolio, helping readers navigate complex legal and financial disclosures more efficiently.
XOMA Royalty Corporation (XOMAP) entered into a merger with HilleVax, Inc. under an Agreement and Plan of Merger dated August 4, 2025, after a related tender offer described in an Offer to Purchase dated August 18, 2025. At the Effective Time, Merger Sub merged into HilleVax and HilleVax became a wholly owned subsidiary of XOMA, with outstanding HilleVax shares (subject to customary exceptions) cancelled and converted into the right to receive the Offer Price, comprised of a cash amount and a non-transferable Contingent Value Right (CVR).
A Contingent Value Rights Agreement dated September 17, 2025 governs potential cash payments under the CVR, with Broadridge named as rights agent and Dr. Robert Hershberg as initial representative of holders. The filing attaches the Merger Agreement, the CVR Agreement, and a press release incorporated by reference.